Upon delivery of insulin-loaded PLGA nanospheres to the lungs, the systemic levels of glucose showed a significant reduction, leading to hypoglycemia over 48 h, in comparison with the aqueous solution of insulin, which only showed a basal glucose level during 6 h after administration, being rapidly recovered to the initial level [93]. The gene discussed is INS; the disease is Hypoglycemia.